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Abstract 
BACKGROUND: Hepcidin, a small peptide hormone, is established as the main regulator of iron homeostasis. 
AIM: To estimate serum hepcidin, ferritin, and hepcidin: ferritin ratio in β-thalassemia patients and to determine 
the effect of splenectomy and hydroxyurea on serum hepcidin. 
METHODS: A study was conducted on 30 thalassemia major (βTM), 29 thalassemia intermedia (βTI) and 29 
healthy children's controls. Data were collected by patient interviewing where detailed history-taking and thorough 
clinical examinations were carried out. Serum ferritin and hepcidin were measured by ELISA assay (Bioneovan 
Co. Ltd Beijing, China). 
RESULTS: Βeta-thalassemia patients had higher serum ferritin, serum hepcidin and lower Hb and hepcidin: 
ferritin ratio compared to the controls (p < 0.001, 0.010, 0.001, 0.001) respectively. Β-TM patients had higher 
mean serum hepcidin and serum ferritin compared to β-TI, with statistically significant difference (P = 0.042, P < 
0.001, respectively). Twenty-one patients out of 29 βTI was on hydroxyurea therapy; these patients had 
significantly lower levels of serum ferritin (P < 0.004) and significantly higher levels of Hb (P < 0.004). Serum 
ferritin was statistically significantly higher in splenectomized patients P < 0.009. Serum hepcidin level was 
insignificantly higher in splenectomized patients than non-splenectomized patients (21.6 ± 14.75, 17.76 ± 10.01 
ng/mL). Hepcidin showed a significantly positive correlation with hepcidin: ferritin ratio in all studied groups. 
CONCLUSION: Serum hepcidin was elevated in β-thalassemia children with more evident elevation in βTM 
patients. Splenectomy played no major role in hepcidin regulation. Knowing that hepcidin in serum has a dynamic 
and multi-factorial regulation, individual evaluation of serum hepcidin and follow up, e.g. every 6 months could be 
valuable, and future therapeutic hepcidin agonists could be helpful in management of iron burden in such patient. 
 
 
 
 
Introduction 
 
Thalassemia remains a major haematological 
health problem in Egypt. Β- thalassemia is autosomal 
recessive anaemia resulting from impaired 
biosynthesis of the β-globin chain [1]. This disorder of 
β-chain synthesis leads to ineffective erythropoiesis. 
Erythroid progenitor cells undergo intramedullary 
apoptosis and do not develop into mature 
erythrocytes.The basic mechanism of iron overload in 
children with β-thalassemia intermedia (TI) is the 
acceleration of the production of RBCs due to 
ineffective erythropoiesis [2], [3]. In children with β-
thalassemia major (βTM) an adequate blood 
transfusion program decreases the complications of 
anaemia and compensatory bone marrow expansion, 
allows normal development throughout childhood, and 
extends survival [4]. Iron overload due to both 
transfused iron and increased iron absorption is 
common in βTM. 
Significant progress was developed in 
clarifying the iron metabolism pathway. Hepcidin a 
small peptide hormone is established as main 
regulator of iron homeostasis. It inhibits iron entry into 
the plasma from the main sources of iron: dietary 
absorption, the release of stored iron from 
hepatocytes and the release of recycled iron from 
macrophages. However, in transfused patients higher 
hepcidin levels resulted in macrophage iron loading, 
whereas in nontransfused thalassemia, iron was 
deposited in hepatocytes [5]. Hepcidin is synthesized 
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as prohepcidin that is converted to its bioactive form 
by hepatocytes, secreted into the bloodstream, and 
excreted by the kidneys [5]. 
Furthermore, hepcidin is also synthesised in 
the spleen of normal mice and induced by 
lipopolysaccharide [6]. Camberlein et al. reported that 
hepcidin has led to restriction of iron export from the 
spleen, in a mouse model of secondary iron overload 
[7]. However, many authors reported that hepcidin is 
also produced from various tissues and organs, 
including adipose tissue, macrophages, monocytes 
and kidney, but at a lower level than that produced by 
the liver and the role of hepcidin in these cell types is 
unclear [8], [9], [10], [11]. Thalassemia is a good 
model to show the dynamic regulation of hepcidin in 
the face of competing influences of coexistent 
anaemia, expanded erythropoiesis and iron loading. 
Hepcidin level is variable in children with β-
thalassemia [12], [13]. Cases with marked anaemia 
and high erythropoietic activity had hepcidin 
deficiency [14], but in case of iron overload, hepcidin 
expression will be increased [15]. In β-thalassemia, 
usually we depend on serum ferritin measurements to 
diagnose iron overload [16]. Knowing that, 
erythropoiesis measurably fluctuates over the inter-
transfusion interval, thus we must standardized the 
timing of measurement of indices for the research 
purposes (e.g. immediately pre-transfusion) [12]. 
Spleen is the most commonly affected organ 
in children with thalassemia. Splenomegaly is the 
result of extramedullary hematopoiesis, excessive 
destruction of abnormal RBCs, and transfusion 
overload. Splenomegaly further increases transfusion 
requirement. Splenic macrophages remove damaged 
RBCs passing through the red pulp of the spleen. 
Splenectomy is one possible therapeutic approach to 
the management of severely affected patients. 
Splenectomy is indicated when hypersplenism 
increases blood transfusion requirement and prevents 
adequate control of body iron with chelating therapy 
[17]. 
This study was conducted to estimate serum 
hepcidin, ferritin and hepcidin: ferritin ratio in β- 
thalassemia patients treated with hydroxyurea and 
different chelating therapy. Also, we aimed to 
determine the effect of splenectomy on serum 
hepcidin. 
 
 
Patients and Methods  
 
The current case-control study was conducted 
in Pediatrics Clinic in the Centre of Excellence in 
National Research Centre and El Helal Giza Children 
Hospital haematology Clinic in 2018.The study 
included 59 patients, 30 TM and 29 TI. Patients 
consisted of 35 (59.3%) boys and 24(40.7%) girls. 
Their age ranged from 3 – 17 y (mean age was 9.1 ± 
3.7 y) and were diagnosed as β-TM and β-TI based 
on conventional clinical and hematologic criteria [18]. 
The exclusion criteria were ethose with concurrent 
infection, chronic inflammatory disorders or liver 
dysfunction. Also, 29 healthy subjects with matching 
age and sex were included as a control group. All 
patients and healthy subjects gave informed consent 
form to participate in the present study, approved by 
National Research Centre Ethics Committee. Data 
were collected by reviewing medical records as well 
as patient interviewing where detailed history-taking 
and thorough clinical examinations were carried out. 
Blood was collected before blood transfusion. 
 
Sample Collection 
Four ml of venous blood were withdrawn 
under aseptic conditions; blood was centrifuged to get 
serum to measure liver function and kidney function 
tests. Serum samples then were stored in -80°C for 
assessment of serum ferritin and hepcidin. 
 
Laboratory Investigation 
 Liver function and kidney function tests were 
done by using an autoanalyser Olympus AU400 
(Olympus America Inc, Center Valley, Pa, USA). 
Serum ferritin and hepcidin were measured by ELISA 
assay (Bioneovan Co. Ltd Beijing, China) 
 
Statistical analysis 
The standard computer program Statistical 
Package for the Social Sciences (SPSS) for Windows, 
release 17.0 (SPSS Inc., USA) was used for data 
entry and analysis. All numeric variables were 
expressed as mean ± standard deviation (SD). The 
intergroup comparisons were performed by using an 
independent-sample t-test and a one-way analysis of 
variance and Chi-Square tests for categorical 
variables. Pearson’s and Spearman’s correlation tests 
(r=correlation coefficient) were used for correlating 
normal and nonparametric variables, respectively. 
Linear multiple regression was run to predict Hepcidin. 
Receiver operating curve (ROC) analysis was done to 
test the validity of hepcidin vs hepcidin to ferritin ratio 
in detecting iron overload. For all tests, a P-value of 
less than 0.05 was considered significant. 
 
 
Results  
 
The mean age of the children with TM, TI and 
control were 10.3 ± 4.2 years (from 4 to 17 years), 9.1 
± 3.7 years (from 3 to 16 years) and 10.4 ± 4.2 years 
(from 2 to 18 years old) respectively, and there was 
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no statistically significant difference between the three 
groups (P = 0.43) by ANOVA. Considering gender 
distributions, 21 (43.8%) and 22 (55%). 
Of the subjects in the TM and TI groups were 
female, respectively; Considering gender distributions, 
patients consisted of 35 (59.3%) boys and 24 (40.7%) 
girls, there was no statistically significant difference (P 
= 0.39). Also, there were no statistically significant 
differences in serum hepcidin levels between males 
and females in patients with TM and TI (P = 0.30 and 
P = 0.56 respectively). Table 1 shows the comparison 
of Clinical and Laboratory Data of β- thalassemia 
Patients with controls. Β-thalassemia patients had 
higher serum ferritin, serum hepcidin, lower Hb and 
hepcidin: ferritin ratio compared to the control group (p 
< 0.001, 0.010, 0.001, 0.001, respectively). 
Table 1: Comparison of Clinical and Laboratory Data of β-
thalassemia Patients With controls 
  N Mean Std. Deviation Sig. (2-tailed) 
Age (Years) 
β-thalassemia 
Patients 
59 9.18 3.70 0.193 
Controls 29 10.34 4.24  
Hb (g/dL) 
β-thalassemia 
Patients 
59 7.24 1.03 0.001 
Controls 29 11.68 1.08  
Ferritin 
(ng/mL) 
β-thalassemia 
Patients 
59 1581.6 787.64 0.001 
Controls 29 141.9 55.33  
Hepcidin 
(ng/mL) 
β-thalassemia 
Patients 
59 19.73 12.98 0.010 
Controls 29 13.01 6.46  
Hepcidin:ferritin 
Ratio 
β-thalassemia 
Patients 
59 0.023 0.043 0.001 
Controls 29 0.094 0.0365  
 
When the two groups of thalassemia (TM, TI) 
were considered separately, age and hepcidin: ferritin 
ratio showed no statistically significant difference 
between the two groups. On the other hand, β-TM 
patients had higher mean serum hepcidin, serum 
ferritin, lower Hb and lower number of weeks between 
transfusions compared to β-TI, with statistically 
significant difference (P.042, P < 0.001 respectively) 
(Table 2). 
Table 2: Comparison of Clinical and Laboratory Data of 
Patients With β-Thalassemia Major and Intermedia 
  N Mean Std. Deviation Sig. (2-tailed) 
Age (Years) 
Βtm 30 9.23 3.80 0.922 
Βti 29 9.13 3.67  
BMI  
(Kg/m
2
)
 
Βtm 30 16.93 3.58 0.791 
Βti 29 17.16 3.02  
No of weeks 
between blood 
transfusion 
Βtm 30 3.80 0.407 0.001 
Βti 29 8.86 5.79  
Hb (g/L) 
Βtm 30 6.59 0.94 0.001 
Βti 29 7.91 0.59  
Ferritin 
(ng/ml) 
Βtm 30 2099.10 574.50 0.001 
Βti 29 1046.37 599.67  
Hepcidin 
(ng/ml) 
Βtm 30 21.74 13.11 0.042 
Βti 29 16.04 9.31  
Hepcidin:Ferritin 
 Ratio 
Βtm 30 0.026 0.057 0.598 
Βti 29 0.020 0.01  
 
Table 3 shows iron chelation therapy 
(deferoxamine = DFO; deferiprone = DFP and 
deferasirox = DFX) in patients with β-thalassemia 
major and intermedia. There was a statistically 
significant difference between the two groups 
regarding the type of chelating agents and the number 
of patients (P < 0.001). Out of 59 patients 17 patients 
with β-thalassemia intermedia did take iron chelation 
therapy. None chelated group had significantly lower 
levels of serum ferritin (787.00 ± 272.04 and 1903.31 
± 693.48 P < 0.001). Also, they had a significantly 
higher mean Hb level (8.16 ± 0.499 and 6.87 ± 0.95 P 
< 0.001). 
Table 3: Types of Chelating Agents in Patients With β-
Thalassemia Major and Intermedia 
 Type of chelation 
Total 
0 DFO 
DFO, 
DFP 
DFP DFX 
β-TM 
 
 
 
β-TI 
Count 0 2 1 9 18 30 
% within Thalassemia 
Major Thalassemia 
Intermedia 
.0% 6.7% 3.3% 30.0% 60.0% 100.0% 
% within Type of chelation .0% 100.0% 100.0% 60.0% 75.0% 50.8% 
Count 17 0 0 6 6 29 
% within Thalassemia 
Major Thalassemia 
Intermedia 
58.6% 0% 0% 20.7% 20.7% 100.0% 
% within Type of chelation 100.0% 0% 0% 40.0% 25.0% 49.2% 
Total Count 17 2 1 15 24 59 
% within Thalassemia 
Major Thalassemia 
Intermedia 
28.8% 3.4% 1.7% 25.4% 40.7% 100.0% 
% within Type of chelation 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Chi-Square Tests P > 0.001; DFO = deferoxamine DFP = deferiprone; DFX = deferasirox. 
 
Twenty-one patients out of 29 βTI were on 
hydroxyurea therapy, these patients had significantly 
lower levels of serum ferritin (P < 0.004) and 
significantly higher levels of Hb (P < 0.004) than other 
patients. The insignificant difference was found in 
serum hepcidin and hepcidin:ferritin ratio between the 
two groups. 
Transfusion dependent TI patients had 
significantly higher serum ferritin (P < 0.001) and 
significantly lower Hb (P < 0.007). Serum hepcidin and 
hepcidin: ferritin ratio showed no statistically 
significant difference between the dependent and non-
dependent groups. 
The relationship between iron overload and 
laboratory data among thalassemia patients are 
shown in Table 4. There was a statistically significant 
difference in number of weeks between blood 
transfusion, Hb g/L, ferritin ng/mL, hepcidin ng/mL and 
hepcidin: ferritin ratio (P < 0.005, 0.001, 0.001, 0.007 
and 0.001) respectively. 
Table 4: Comparison of Clinical and Laboratory Data of 
Patients with Iron Overload and Without 
 Iron overload 
(SF ≥ 1000 ng/ml) 
N Mean 
Std. 
Deviation 
Sig. (2-tailed) 
Age (Years) 
No iron over load 49 9.69 3.92 0.737 
Iron overload 39 9.41 3.92  
BMI  
(Kg/m
2
)
 
No iron over load 20 16.78 3.31 0.671 
Iron overload 39 17.17 3.31  
No of weeks 
between blood 
transfusion 
No iron overload 20 8.65 5.84 0.005 
Iron overload 39 5.08 3.64  
Hb (g/L) 
No iron over load 49 10.17 2.04 0.001 
Iron overload 39 6.86 1.01  
Ferritin 
(ng/ml) 
No iron over load 49 369.70 293.53 0.001 
Iron overload 39 2033.80 564.25  
Hepcidin 
(ng/ml) 
No iron over load 49 14.55 8.68 0.007 
Iron overload 39 21.25 13.79  
Hepcidin:Ferritin 
 Ratio 
No iron over load 49 0.066 0.046 0.001 
Iron overload 39 0.023 0.051  
 
Considering splenectomy, 18 cases out of 59 
(30.5%) had a splenectomy. Although serum hepcidin 
level was higher in splenectomized patients (21.6 ± 
14.75, 17.76 ± 10.01 ng/mL), there was no statistically 
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significant difference in number of weeks between 
blood transfusion, Hb g/L, hepcidin ng/mL and 
hepcidin: ferritin ratio between splenectomized 
patients and non- splenectomized. Serum ferritin 
ng/mL was statistically significantly higher in 
splenectomized patients P < 0.009. Also, 15 out of 18 
splenectomized patients had iron overload (serum 
ferritin ≥ 1000 ng/ml) as shown in Table 5. 
Table 5: Results of splenectomized and non-splenectomized 
TM patients 
 1 = splenomegaly 
0 = splenectomized 
N Mean Std. Deviation Sig. (2-tailed) 
Hepcidin 
1 20 19.7505 11.09305 0.245 
0 10 25.7400 16.37024  
Hipcidin/ 
ferritin 
1 20 0.019520 0.0254222 0.344 
0 10 0.041020 0.0947943  
Ferritin 
1 20 2103.6250 676.38623 0.953 
0 10 2090.0600 312.33822  
Hb 
1 20 6.6750 0.91931 0.514 
0 10 6.4300 1.03500  
 
Hepcidin showed a significantly positive 
correlation with Hepcidin: ferritin ratio in all studied 
groups. Also, it showed a significantly negative 
correlation with age in patients with Β-thalassemia. 
Healthy children hepcidin showed a significantly 
positive correlation with ferritin (r = 0.645, P < 0.001), 
as shown in Table 6. 
Table 6: Results of correlation between serum hepcidin levels 
and the evaluated parameters for all groups 
Group Age, Y 
   r         P 
Ferritin, ng/mL  
     r          P 
Hemoglobin/dL 
   r          P 
Hepcidin/Ferritin 
   r             P  
Β-
Thalassemia 
-0.317* 0.014 -0.014    0.917 0.012   0.930 0.751**   0.001 
Β-TM -0.314  0.091 -0.058    0.760 0.082   0.668 0.747**   0.001 
Β-TI -0.342  0.070 -0.160    0.408 0.199   0.301 0.914**   0.001 
Controls 0.300   0.114 0.645**  0.001 0.173  0.368 0.583**   0.001 
* Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 
level (2-tailed). 
 
Multiple linear regression was run to predict 
hepcidin from Predictors: (Constant), hydroxyurea 
therapy, hepcidin/ ferritin, transfusion, hepcidin, and 
ferritin in diseased children. Serum ferritin and 
hepcidin: ferritin ratio variables were a statistically 
significant predictor of serum hepcidin level (P < 
0.001). 
 
Figure 1: ROC curve of hepcidin  
A receiver operating characteristic curve 
(ROC curve) was done to test the sensitivity and 
specificity of hepcidin and hepcidin/ferritin ratio, in 
predicting iron overload (SF ≥ 1000 ng/ml) at different 
cutoff values. The area under the curve of hepcidin 
was found as 0.628 (P = 0.040) while that of 
hepcidin/ferritin ratio was 0.180 (non-sig), indicating 
that overall predictability of hepcidin is significantly 
high when compared to hepcidin/ferritin ratio (Figure 
1). 
 
 
 
Discussion 
 
Hepcidin level in serum has a dynamic and 
multifactorial regulation. The current study showed 
that β-thalassemia patients of both βTM and βTI had 
significantly elevated serum hepcidin level compared 
to healthy children. Our results were in agreement 
with those of previous studies [19], [20], [21]. On other 
hand, several authors reported undetectable or low 
serum hepcidin in β-TM subjects as compared to 
controls [22], [23], [24], [25], [26]. Hepcidin has a 
complex regulation in β-thalassemia patients. Its 
production is controlled by opposing effects from 
erythropoiesis, anaemia and iron overload. Hepcidin is 
up-regulated by increased body iron levels, infection 
and inflammation; it is down-regulated by many 
factors as anaemia, hypoxia, iron deficiency, 
ineffective erythropoiesis and by increased levels of 
erythropoietin [13], [27], [28], [29].It may be valuable 
to know that other factors might modify the hepcidin 
synthesis in β-thalassemia patients such as genetic or 
laboratory variables [27], [30]. Our data showed that 
patients with βTM had significantly higher serum 
hepcidin than βTI cases. The rate of iron loading is 
higher in βTM than in βTI due to regular transfusions 
also transfusions inhibit erythropoietic drive; both lead 
to an increase of hepcidin in β-TM patients [14], [19], 
[21], [23], [24]. 
Our data showed that serum hepcidin is not 
affected by gender in children with β-thalassemia this 
was in agreement with previous studies [21], [22], 
[23], [24]. 
The current study showed no significant 
difference in serum hepcidin between TI patients 
receiving hydroxyurea and those not receiving 
hydroxyurea, although they had significantly higher 
levels of Hb (P < .004). This means that hydroxyurea 
intake did not affect hepcidin production directly or 
through increasing total haemoglobin level. Or 
probably Hb was not high enough to suppress 
ineffective erythropoiesis and consequently, was not 
able to decrease serum hepcidin level. Our result was 
in agreement with Haghpanah et al., [21], [29]. 
Considering splenectomy, eighteen (30.5%) 
of our patients had been splenectomized. Although 
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serum hepcidin level was higher in splenectomized 
patients, the difference was of no statistical 
significance. Jones et al., reported that the 
inflammatory marker CRP and transferrin saturation 
both were higher in splenectomized patients. Both 
inflammation and transferrin bound iron is known to 
induce hepcidin [1]. Splenectomy in Hb E β-
thalassemia patients was associated with lower serum 
hepcidin; the authors reported that the differences in 
hepcidin were not mediated by a phenotype-
splenectomy interaction [31]. Similar to a previous 
study, we found no difference in Hb between 
splenectomized and non-splenectomized patients [1], 
[32]. There was no apparent difference in hepcidin: 
ferritin ratio between splenectomized patients and 
non- splenectomized patients. 
The authors found that age has no relation 
with hepcidin level among healthy children; this was in 
agreement with previous report [21], [29]. But in 
children with βTM, negative correlation between age 
and hepcidin was reported. Based on the current 
study results, there was insignificant correlation 
between serum hepcidin and ferritin levels in patients 
with βTM and βTI, which supported the results of 
previous studies that regulation of serum hepcidin in 
thalassemia is more affected by erythropoietic activity 
than by iron, overload [29], [33]. 
The hepcidin/ferritin ratio in β-thalassemia 
children was significantly lower (P < 0.0001) than in 
controls suggesting that serum hepcidin level was not 
increased in proportion to the iron overload [13], [29]. 
Hepcidin showed a significantly positive correlation 
with hepcidin: ferritin ratio in all studied groups. 
Using a receiver operating characteristic 
curve (ROC curve) in predicting iron overload, it was 
found that area under the curve (AUC) of hepcidin 
was 0.628; which indicates that the overall 
predictability of hepcidin is significant (p = 0.040). 
Accuracy is measured by the area under the ROC 
curve. An area of .60-.70 represents a poor test; this 
result was similar to a previous study [21]. The result 
means that serum hepcidin was not as good as serum 
ferritin in predicting severe iron overload. 
There were some limitations in the study 
since we did not evaluate molecular erythropoietic 
activity. The liver iron concentration was not available 
for the present cases to be the gold standard of 
assessment of iron overload.  
In conclusion, based on the current study 
results, serum hepcidin was elevated in β- 
thalassemia children with more evident elevation in 
βTM patients. Also serum hepcidin levels were 
significantly higher in the βTM than in βTI patients, 
which could be due to higher erythropoietic activity in 
TI. Splenectomy played no major role in hepcidin 
regulation. There was insignificant correlation 
between serum hepcidin level and serum ferritin level 
as a marker of iron overload in patients with βTM and 
βTI. Knowing that hepcidin in serum has a dynamic 
and multi-factorial regulation, individual evaluation and 
follow up, e.g. every 6 months could be valuable in 
diagnosing and managing iron burden in such patient. 
Future therapeutic hepcidin agonists could be helpful 
in management of iron burden in β thalassemia.  
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